Protocol Name: Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants with APOL1-Mediated Kidney Disease
Protocol #: D6800C00005
Indication: APOL1-Mediated Proteinuric Kidney Disease
GFR: ≥ 25
Principal Investigator: Akinwande Akinfolarin
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246